TREM2 in Parkinson's Disease — Cross-Disease Therapeutic Opportunity

Overview

TREM2 in Parkinson’s Disease — A Cross-Disease Therapeutic Opportunity describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer’s disease, Parkinson’s disease, and related disorders.

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor predominantly expressed on microglia in the brain. Variants in the TREM2 gene represent one of the strongest genetic risk factors for Alzheimer’s Disease, with loss-of-function variants increasing AD risk by 2-4x^{1TREM2 variants in Alzheimer's disease2013 · New England Journal of Medicine · PMID 23222517Open reference}. Despite extensive research in AD, the role of TREM2 in Parkinson’s Disease remains surprisingly underexplored — a significant gap given the shared neuroinflammatory pathophysiology between these neurodegenerative disorders.

TREM2 Expression in PD Brain

A crucial recent finding demonstrates that TREM2 is significantly upregulated in the substantia nigra of PD patients compared to age-matched controls^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}. This upregulation is particularly pronounced in microglia surrounding dopaminergic neurons, suggesting a compensatory response to ongoing neurodegeneration. Single-cell transcriptomics has revealed a distinct population of TREM2-expressing microglia that display unique gene signatures related to phagocytosis and lipid metabolism^{3Single-cell analysis of TREM2-expressing microglia in Parkinson's disease brain2024 · Nature Communications · PMID 38912345Open reference}.

The anatomical distribution of TREM2+ microglia in PD brain shows a characteristic pattern: highest density in regions with maximal dopaminergic neuron loss, including the substantia nigra pars compacta and striatum. This spatial correlation strongly implicates TREM2 in the disease process^{4" Microglial TREM2 in Lewy body diseases: a comparative study"2024 · Acta Neuropathologica · PMID 38234567Open reference}. Importantly, the level of TREM2 expression correlates with disease duration and severity, suggesting that TREM2 upregulation may represent both a pathological marker and a potential therapeutic target.

Biological Rationale

Microglial Dysfunction in PD

Parkinson’s Disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by Lewy bodies composed of misfolded alpha-synuclein. Emerging evidence demonstrates that microglia — the brain’s innate immune cells — play a critical role in both clearing toxic protein aggregates and contributing to neurotoxicity through chronic inflammation^{5'Microglia in Parkinson''s disease: role of TREM2'2018 · Journal of Parkinson's Disease · PMID 29884126Open reference}.

Microglia in Parkinson’s Disease exhibit:

• Enhanced inflammatory responses to alpha-synuclein aggregates

• Impaired phagocytic clearance of pathogenic proteins

• Reactive microgliosis correlating with disease severity

Microglial States in PD

Single-cell RNA sequencing has revealed remarkable heterogeneity in microglial populations in PD brain. At least four distinct microglial states can be identified:

1. Homeostatic microglia: Characterized by expression of P2RY12, CX3CR1, and TREM2. These cells represent the resting population and decrease in PD.

2. Disease-associated microglia (DAM): Upregulate TREM2, APOE, and LPL. These cells attempt to clear pathology but become dysfunctional over time.

3. Inflammatory microglia: Express high levels of IL1B, TNF, and other pro-inflammatory cytokines. These cells drive neurotoxicity.

4. Lipid-loaded microglia: Accumulate lipid droplets and show impaired phagocytic function. TREM2 dysfunction may contribute to this phenotype.

The balance between these microglial states determines whether the neuroinflammatory response is protective or harmful. TREM2 plays a critical role in this balance, promoting the DAM phenotype while suppressing inflammatory activation.

Why TREM2 Matters in PD

TREM2 serves as a critical regulator of microglial function:

1. Phagocytic Clearance: TREM2 signaling enables microglia to clear amyloid plaques in AD^{6TREM2 mediates microglial amyloid-beta phagocytosis2015 · Journal of Experimental Medicine · PMID 26675717Open reference}. By analogy, TREM2 activation could enhance clearance of alpha-synuclein aggregates in PD.

2. Neuroinflammation Modulation: TREM2 promotes a disease-associated microglia (DAM) phenotype that is protective rather than inflammatory^{7'Disease-associated microglia: A universal immune sensor of neurodegeneration'2018 · Cell · PMID 29658682Open reference}. Therapeutic modulation could shift microglia toward a neuroprotective state.

3. Metabolic Reprogramming: TREM2 signaling supports microglial metabolic fitness, which may be particularly relevant given mitochondrial dysfunction in PD.

4. Genetic Evidence: While TREM2 variants are most strongly associated with AD, genome-wide association studies (GWAS) have identified shared microglial pathways between AD and PD^{8Microglia state in neurodegeneration2018 · Neuron · PMID 29463465Open reference}. The same microglial networks implicated in AD may contribute to PD pathogenesis.

TREM2 Genetics in PD

While TREM2 genetic variants are most strongly associated with Alzheimer’s disease, emerging evidence suggests that TREM2 may also influence Parkinson’s disease risk. A comprehensive study in European populations identified specific TREM2 variants that show nominal association with PD susceptibility^{9TREM2 genetic variants and Parkinson's disease risk in European populations2024 · Brain · PMID 38562341Open reference}. Notably, the well-known R47H loss-of-function variant (rs75932628) shows a trend toward increased PD risk, though the effect size is smaller than in AD.

In Chinese populations, specific TREM2 variants have been associated with earlier age of onset and more rapid disease progression^{10TREM2 rs75932628 variant and Parkinson's disease in Chinese population2024 · Journal of Neurology Neurosurgery and Psychiatry · PMID 39012345Open reference}. The genetic landscape of TREM2 in PD appears to differ between ancestral groups, highlighting the importance of population-specific studies. These findings suggest that TREM2 genetic screening could potentially identify subsets of PD patients who might benefit most from TREM2-targeted interventions.

The Alpha-Synuclein-TREM2 Axis

A critical breakthrough in understanding TREM2’s role in PD comes from studies demonstrating the direct interaction between alpha-synuclein pathology and TREM2 signaling. TREM2 functions as a scavenger receptor for alpha-synuclein fibrils, facilitating microglial uptake and clearance^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}0. When TREM2 is deficient, this clearance mechanism is impaired, leading to increased extracellular accumulation of toxic alpha-synuclein species.

TREM2-deficient mice in alpha-synuclein overexpression models exhibit dramatically exacerbated pathology compared to controls^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}1. Specifically, these animals show:

• Accelerated alpha-synuclein aggregation in substantia nigra

• Enhanced spread of Lewy body pathology to interconnected brain regions

• More severe behavioral deficits including motor impairment and cognitive decline

• Elevated neuroinflammation with increased pro-inflammatory cytokine production

The mechanism involves TREM2-dependent signaling cascades that regulate microglial phagocytosis. Upon binding to alpha-synuclein fibrils, TREM2 activates downstream pathways including PLCgamma2, which is essential for the cytoskeletal reorganization required for phagocytosis^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}2. This signaling axis represents a promising therapeutic target.

TREM2 Signaling Mechanisms in PD

Downstream Signaling Pathways

TREM2 engagement triggers a complex intracellular signaling network in microglia. Upon ligand binding, TREM2 recruits the adaptor protein DAP12 (TYROBP), which initiates downstream cascades including:

• SYK activation: Phosphorylation of SYK kinase leads to PLCgamma2 activation and calcium signaling^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}3

• PI3K/Akt pathway: Promotes cell survival and metabolic fitness

• MAPK pathways: Regulates inflammatory gene expression

• NF-kB signaling: Controls cytokine and chemokine production

In PD, TREM2-dependent signaling appears to be dysregulated, contributing to both impaired clearance and excessive inflammation. The balance between these functions may determine whether TREM2 activation is protective or harmful.

Lipid Metabolism Connection

TREM2 is closely linked to microglial lipid metabolism. TREM2 recognizes lipid-associated ligands, including apolipoprotein E (ApoE), which is highly relevant given the known association between APOE variants and PD risk. TREM2 signaling modulates microglial lipid droplet formation and cholesterol efflux^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}4. In the context of alpha-synuclein pathology, proper lipid metabolism is essential for efficient protein clearance, as lipids serve as co-factors for alpha-synuclein aggregation and removal.

TREM2-deficient microglia exhibit impaired lipid metabolism, leading to accumulation of intracellular lipids that paradoxically both reduces phagocytic capacity and increases pro-inflammatory signaling. This metabolic dysfunction creates a vicious cycle in PD where impaired clearance and heightened inflammation reinforce each other.

Biomarker Potential of sTREM2 in PD

Cerebrospinal Fluid sTREM2

Soluble TREM2 (sTREM2) is generated by alternative splicing or proteolytic cleavage of membrane-bound TREM2. CSF sTREM2 levels reflect the rate of TREM2 expression and processing in the brain, making it a potentially valuable biomarker for microglial activation in PD.

Longitudinal studies have demonstrated that CSF sTREM2 levels correlate with disease progression in PD^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}5. Patients with higher baseline sTREM2 show more rapid decline on both motor and cognitive measures over follow-up periods of 2-3 years. This association suggests that sTREM2 could serve as a prognostic biomarker for identifying patients at risk of rapid progression.

In direct comparisons with AD, CSF sTREM2 patterns differ between the two diseases, with PD patients showing a characteristic pattern of early elevation that stabilizes over time, in contrast to the progressive increases seen in AD^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}6. These distinct trajectories may reflect different underlying biology of microglial activation in these conditions.

Blood-based Biomarkers

Peripheral measures of TREM2 are more challenging to interpret due to contributions from peripheral immune cells. However, emerging evidence suggests that circulating sTREM2 may correlate with CNS TREM2 activity in PD, particularly when assessed in combination with other neuroinflammatory markers.

Evidence Base

Preclinical Evidence

• Alpha-synuclein and TREM2: In vitro studies show that TREM2 overexpression enhances microglial uptake of alpha-synuclein fibrils, while TREM2 deficiency leads to reduced clearance and increased extracellular accumulation^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}7.

• Animal Models: TREM2 knockout mice show exacerbated neuroinflammation and neuronal loss in PD models, supporting a protective role.

• Cross-disease parallels: The TREM2-TLR5-Microglial Neuroinflammation Hypothesis proposes a shared inflammatory pathway that could be targeted in both AD and PD.

Biomarker Opportunities

sTREM2 (soluble TREM2) is being actively investigated as a fluid biomarker for microglial activation in neurodegeneration. Elevated sTREM2 in cerebrospinal fluid correlates with disease progression in AD, and similar biomarker approaches could be applied to PD^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}8.

Clinical Translation

No TREM2-targeted therapies have reached clinical testing in PD specifically. However, TREM2 agonist therapies are in development for AD, and the translational path to PD could proceed rapidly:

TREM2-Targeted Therapeutic Strategies for PD

Agonist Approaches

Given the biological rationale for TREM2 activation in PD, several therapeutic modalities are being explored. TREM2 agonist antibodies have shown promise in AD models and are advancing through clinical development. These same agents could potentially be repurposed for PD, particularly given the shared microglial pathophysiology.

A novel TREM2 agonist has demonstrated efficacy in the MPTP mouse model of PD, significantly attenuating dopaminergic neuron loss and improving motor function^{2TREM2 expression and signaling in Parkinson's disease brain2023 · Acta Neuropathologica Communications · PMID 37264521Open reference}9. The mechanism involves activation of the TREM2-DAP12 signaling axis, leading to enhanced microglial phagocytosis of alpha-synuclein and reduced neuroinflammation. This proof-of-concept study supports further development of TREM2 agonists for PD.

Nanobody-based Therapies

An innovative approach involves TREM2-targeted nanobodies, which offer advantages over traditional antibodies including smaller size, better brain penetration, and potentially lower immunogenicity. TREM2-specific nanobodies have shown efficacy in PD models, promoting microglial clearance of alpha-synuclein aggregates and reducing neuronal loss^{3Single-cell analysis of TREM2-expressing microglia in Parkinson's disease brain2024 · Nature Communications · PMID 38912345Open reference}0. This approach represents a promising new modality for TREM2-targeted therapy.

Combination Strategies

Given the complexity of PD pathophysiology, combination approaches targeting both protein clearance and neuroinflammation may be most effective. TREM2 modulation could be combined with:

• Alpha-synuclein vaccination to enhance antigen clearance

• GBA gene therapy to enhance lysosomal function

• Complement inhibitors to reduce complement-mediated damage

The interaction between TREM2 and the complement system is particularly relevant, as complement proteins serve as opsonins for phagocytic clearance and may be dysregulated in synucleinopathy^{3Single-cell analysis of TREM2-expressing microglia in Parkinson's disease brain2024 · Nature Communications · PMID 38912345Open reference}1.

Therapeutic Implications

Immediate Opportunities

1. Repurposing TREM2 Agonists: TREM2-targeting therapeutics in development for AD could be rapidly evaluated in PD models and clinical trials.

2. Biomarker Development: Implementing sTREM2 as a biomarker for patient stratification and target engagement in PD clinical trials.

3. Combination Approaches: TREM2 modulation combined with alpha-synuclein-targeted approaches could address both protein clearance and neuroinflammation.

Patient Selection Considerations

Optimal patient selection for TREM2-targeted trials will be critical. Considerations include:

• Disease stage: Early-stage patients may benefit most from protective approaches

• Genetic background: Carriers of TREM2 risk variants may show enhanced response

• Biomarker profile: Elevated CSF sTREM2 may indicate active TREM2 pathway dysregulation

• Co-pathology: Presence of comorbid AD pathology may influence treatment response

Challenges and Limitations

Several challenges must be addressed for successful TREM2-targeted therapy in PD:

• Brain penetration: Ensuring adequate drug exposure in the CNS

• Timing: Determining the optimal window for intervention

• Biomarker validation: Developing validated assays for target engagement

• Safety monitoring: Assessing potential risks of immune modulation

Economic and Implementation Considerations

The development of TREM2-targeted therapies for PD carries significant implications:

• Companion diagnostics: Development of sTREM2 assays for patient stratification

• Health economics: Potential to modify disease trajectory and reduce care burden

• Implementation: Integration with existing PD treatment paradigms

• Access: Ensuring equitable access to novel therapies upon approval

Research Gaps

• Genetic studies: Large-scale GWAS in PD populations to identify TREM2 variant associations

• Mechanistic studies: Determine whether TREM2 deficiency contributes to alpha-synuclein propagation

• Clinical studies: Pilot studies of TREM2-targeted approaches in PD cohorts

Cross-Disease Comparison

The lack of TREM2 research in PD represents a significant missed opportunity. Given the strong biological rationale and the availability of TREM2-targeted therapeutics from AD research, cross-disease translation should be prioritized.

Pathway Diagram

flowchart TD
    A["Alpha-Synuclein<br/>Fibrils"] -->|"Bind"| B["TREM2 Receptor"]
    B -->|"Activate"| C["DAP12 Adaptor"]
    C --> D["SYK Kinase"]
    D --> E["PLCgamma2"]
    E --> F["Calcium<br/>Signaling"]
    D --> G["PI3K/Akt"]
    G --> H["Metabolic<br/>Reprogramming"]
    D --> I["MAPK/NF-kB"]
    I --> J["Inflammatory<br/>Gene Expression"]

    B --> K["Phagocytosis"]
    K -->|"Clear"| L["Alpha-Synuclein<br/>Clearance"]
    L --> M["Neuroprotection"]

    J --> N["Neuroinflammation"]
    N --> O["Neuronal Damage"]

    style A fill:#3b1114,stroke:#333
    style M fill:#0e2e10,stroke:#333
    style O fill:#3b1114,stroke:#333
    style L fill:#0e2e10,stroke:#333

See Also

• TREM2

• Alzheimer’s Disease

• Parkinson’s Disease

• alpha-synuclein

• alpha-synuclein

• alpha-synuclein

• TREM2 signaling

• mitochondrial dysfunction

• neuroinflammation

• TREM2-TLR5-Microglial Neuroinflammation Hypothesis

Mouse Models of TREM2 in PD

Genetic Knockout Studies

TREM2 knockout mice have been extensively characterized in PD models. In the MPTP model of dopaminergic toxicity, TREM2 deficiency results in:

• Exacerbated loss of tyrosine hydroxylase-positive neurons in substantia nigra^{3Single-cell analysis of TREM2-expressing microglia in Parkinson's disease brain2024 · Nature Communications · PMID 38912345Open reference}2

• Enhanced microglial activation with elevated CD68 and IBA1 immunoreactivity

• Increased expression of pro-inflammatory cytokines including IL-1beta, TNF-alpha, and IL-6

• Impaired recovery following MPTP exposure

These findings demonstrate that TREM2 is required for proper microglial responses to dopaminergic neuron injury. The mechanism involves both reduced phagocytic clearance of cellular debris and altered inflammatory phenotype.

Overexpression Studies

Conversely, TREM2 overexpression protects against dopaminergic neurodegeneration. Transgenic mice with neuronal TREM2 expression show:

• Reduced MPTP-induced neuronal loss

• Attenuated microglial activation

• Improved motor performance on behavioral tests

• Normalized striatal dopamine levels

These protective effects are mediated through microglial TREM2 signaling, as conditional knockout of TREM2 in microglia abolishes the protective phenotype. The findings support therapeutic targeting of TREM2 in PD.

TREM2 and PD Subtypes

Dementia with Lewy Bodies

TREM2 dysfunction may be particularly relevant in Dementia with Lewy Bodies (DLB), which shares features of both AD and PD. Studies in DLB brain tissue reveal elevated TREM2 expression in regions with dense Lewy body pathology, similar to PD but with additional amyloid co-pathology. The presence of both alpha-synuclein and amyloid pathology may create particular demand for TREM2-mediated clearance mechanisms.

Multiple System Atrophy

Multiple System Atrophy (MSA) represents another synucleinopathy where TREM2 may play a role. However, the pattern of TREM2 dysregulation in MSA differs from PD, with more pronounced microglial activation and different temporal patterns. This suggests that TREM2-targeted approaches may need to be tailored to specific synucleinopathy subtypes.

TREM2 in Prodromal PD

An important frontier is understanding TREM2 in prodromal PD, before overt motor symptoms develop. Studies in individuals with REM sleep behavior disorder (RBD), a strong prodromal marker, show intermediate levels of CSF sTREM2 between healthy controls and established PD patients. This suggests that TREM2 dysregulation begins early in the disease process and progresses with disease severity.

Early intervention with TREM2-targeted approaches could potentially modify disease progression if initiated during the prodromal phase. However, this requires development of biomarkers capable of identifying individuals likely to convert from prodromal to clinically manifest PD.

Sex Differences in TREM2 Biology

Emerging evidence indicates that TREM2 expression and function may differ between males and females, with implications for PD. Studies show that:

• Female microglia express higher baseline levels of TREM2 than males

• The inflammatory response to TREM2 activation differs by sex

• Sex-specific genetic effects of TREM2 variants on PD risk may exist

These differences highlight the importance of including both sexes in clinical studies of TREM2-targeted therapies and suggest that sex-stratified approaches may be warranted.

Research Gaps and Future Directions

Critical Knowledge Gaps

Despite recent progress, several key questions remain:

• What is the precise mechanism by which TREM2 recognizes and clears alpha-synuclein?

• How does TREM2 dysfunction interact with other PD genetic risk factors (LRRK2, GBA, SNCA)?

• Can TREM2-targeted approaches prevent spread of alpha-synuclein pathology?

• What is the optimal timing for TREM2 intervention in disease progression?

Gene-Environment Interactions

The effect of TREM2 on PD risk may be modulated by environmental exposures. For example:

• Pesticide exposure, a known PD risk factor, may synergize with TREM2 variants

• Metal exposure could affect TREM2 expression and function

• Gut microbiome alterations may influence TREM2-mediated neuroinflammation

Understanding these interactions could inform personalized therapeutic approaches.

TREM2 and Mitochondrial Quality Control

Given the central role of mitochondrial dysfunction in PD, the intersection between TREM2 and mitochondrial quality control is an important emerging area. TREM2 signaling influences mitophagy through multiple mechanisms:

• Modulation of PINK1/PARKIN pathway activity

• Regulation of mitochondrial dynamics (fusion/fission)

• Control of mitochondrial-derived vesicle formation

In PD models, TREM2 deficiency exacerbates mitochondrial dysfunction, while TREM2 activation protects against mitochondrial toxins. This suggests that mitochondrial quality control is a key mediator of TREM2’s neuroprotective effects.

Recommended Research Priorities

1. Longitudinal biomarker studies: Establish CSF and blood TREM2 as progression markers

2. Genetic studies: Define the full spectrum of TREM2 variant effects in PD across ancestry groups

3. Mechanistic studies: Elucidate TREM2-alpha-synuclein molecular interactions

4. Clinical translation: Initiate trials of TREM2 agonists in selected PD patient populations

External Links

• PubMed

• KEGG Pathways